Basel (ots) - The 4th European Conference "Tobacco or Health" takes place in Basel from 11th-13th October, 2007. The conference is organized by the Swiss Cancer League together with the German Cancer Society on behalf of the Association of European Cancer Leagues. About 800 participants from over 60 countries ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an Anticalin® ...
- Transaction creates a leading laboratory services group in Europe operating under the name "Unilabs" - Binding purchase agreement signed with Unilabs' majority shareholders to acquire 50.08% of the Unilabs voting rights and 38.10% of the capital - Intention to launch public tender offer at CHF 57.50 per Unilabs bearer Unanimous support of transaction by Unilabs Board of Directors ...
Plan-les-Ouates (ots) - Viroblock SA, a start-up dedicated to developing and commercializing a new generation of antiviral products, today announced that it has completed its first round of equity funding led by private investor Peter Pfister, Fongit Seed Invest SA, and Initiative Capital Romandie SA. Viroblock also announced that the newly appointed Board of Directors will consist of Peter Pfister (Chairman), ...
Aachen (ots) - The German pharmaceutical company Grunenthal announces its worldwide exclusive rights on trimegestone for the use in oral contraception by Aventis Pharma, SA, France, a subsidiary of sanofi-aventis. Thereby the firm extends its gynaecological pipeline. Trimegestone will be developed as a new oral contraceptive component derived from natural ...
European Society for Medical Oncology (ESMO)
PLEASE NOTE: FULL TEXT OF THE PRESS RELEASES AVAILABLE THROUGH WWW.ESMO.ORG/PRESSROOM upon registration PLEASE RESPECT INDIVIDUAL EMBARGO DATES/TIMES FOUND ON FULL PRESS RELEASES Lugano (ots) - HORMONE INHIBITOR PROMISING FOR HARD-TO-TREAT PROSTATE CANCER For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully demonstrated dual targeting potential. Commenting on this development, Dr ...
Aachen (ots) - The German pharmaceutical company Grunenthal GmbH presented the first clinical evidence for the efficacy and tolerability of tapentadol ER (extended release) for patients suffering from chronic pain at the Annual Congress of the European League Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, a centrally acting analgesic, ...
pro adicta - escape Ambulatorium
Schoeftland (ots) - pro adicta facilitates the treatment of addiction to opioids such as heroin and methadone by means of escape, an innovative method of treatment using neuroelectric stimulation. Drug addiction can be overcome more easily using neuronal stimulation. On the basis of the latest knowledge in the ...
Barcelona (ots) - New Results Represent Additional Data From a Study Showing Superior Efficacy of ORENCIA or Infliximab Compared to Placebo at Six Months Bristol-Myers Squibb Company (NYSE: BMY) today announced additional study results providing evidence of the efficacy and durability of response of ORENCIA(R) (abatacept) through 12 months in adults with ...
Freising-Weihenstephan (ots) - Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, announced today it has demonstrated potent anti-tumor activity of PRS-050. The positive results with PRS-050, a VEGF-specific ...
Bettlach (ots) - Mathys, the Bettlach-based orthopaedics business, recruited a further 28 persons in 2006. At 7.2 %, the increase in turnover was less than expected, but was nonetheless substantially higher than the industry average. This family-owned business achieved consolidated sales of CHF 74.2 million, which, although equivalent to a year-on-year increase of 7.2 %, was slightly less than expected. The slower ...
Aachen, Germany (ots) - Grünenthal GmbH announced that it has extended a licensing agreement with Ortho-McNeil Pharmaceutical, Inc. for tapentadol to include the Japanese market. Ortho-McNeil Pharmaceutical plans to arrange for the development of tapentadol for marketing in Japan. Ortho-McNeil"s affiliate, ...
Aachen, Germany (ots) - In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Versatis®, a novel 5 % lidocaine medicated plaster, for the treatment of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN), developed by the German drug company Grünenthal. Following this national approval of Versatis® and its national launch on January, ...
- During a press conference in Geneva this morning, Martin Velasco, Pascal Mock MD and Prof. Patrick Aebischer, President of the EPFL (Ecole Polytechnique Fédérale de Lausanne), presented a solution which opens promising new prospects in terms of assisted reproductive technology. - A major advantage of the ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced the successful completion of two phase 3 trials of Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV). Both clinical trials successfully met the primary ...
Alvarez & Marsal Development LLC and Dr. Heinz-Dieter Kals Announce World Class Partnership in State of the Art Cancer Therapy Dusseldorf (ots) - ION Boston Management GmbH, which is 50%-owned by Alvarez & Marsal Development LLC and Dr. Heinz-Dieter Kals, has entered into a Radiology Oncology Associates ...
AC Immune, Ltd. enters into an Exclusive Global License Agreement and Research Collaboration with Genentech, Inc. for Development of Anti-beta-amyloid Antibodies for the Potential Treatment of Alzheimer's Disease and other human Diseases. Ecublens/Lausanne, Switzerland (ots) - AC Immune, Ltd., a Swiss Biotech Company developing innovative therapies against Alzheimer's Disease, today announced that it has entered into ...
Freising-Weihenstephan/Germany (ots) - Crystallographic analysis of Anticalin® targeting CTLA-4 confirms the excellent suitability of Pieris' lipocalin scaffold to develop superior biotherapeutics Pieris AG, a biopharmaceutical company developing therapeutic products comprising Anticalins®, a novel ...
Provide Benefit of Improved Mood Disturbance for People With Restless Legs Syndrome GLASGOW, Scotland (ots) - - FOR HEALTHCARE JOURNALISTS (For media outside the US only) - New Data Shows pramipexole is an Effective Treatment Option for the Broad Range of RLS Symptoms During Both the Night and Daytime New data indicate that when treated with pramipexole (Sifrol(R)/Mirapexin(R)), ...
Lugano (ots) - New evidences confirm the assets of Original Nimesulide(1): multifactorial pharmacological activity, fast analgesic action, proven clinical efficacy Presented at Helsinn Satellite Symposium "A valuable common approach to the treatment of different pain conditions " 12th International Pain Clinic Congress 2006, World Society of Pain Clinicians Turin (Italy), 4-7 July 2006 New ...
Amsterdam (ots) - - New Pan-European Sociological Survey Announced by the European Parkinson's Disease Association (EPDA), Reveals the 'Hidden Face' of PD Over 80 percent of surveyed people with Parkinson's disease (PD) 'often' or 'sometimes' suffer from depressive symptoms as part ...
Aachen (ots) - Tapentadol would be the first new molecular entity in the class of oral centrally acting analgesics to enter medical practice in over 25 years. At the American Pain Society Meeting in San Antonio, Texas, Grünenthal GmbH presented positive results on preclinical and early clinical studies of ...
Mittelhäusern (ots) - MEDISTICK GmbH, a young Swiss company, has developed what they believe is the world's first personal multilingual medical record device. The innovative technical software solution on an UBS memory stick format helps to provide swift accurate medical diagnoses and treatments to everybody independent of their whereabouts or language skills. The encrypted software© program loaded on the memory ...
21st Annual Meeting of the European Association of Urology (EAU), Paris, 5th - 8th April 2006 Treatment with degarelix results in fast, profound and sustained reductions in testosterone and prostate-specific antigen (PSA) levels without a testosterone surge Paris (ots) - Following the presentation today of the results of the Phase IIb programme with degarelix in prostate cancer, which are in line with previous ...
Gaithersburg, MD (ots) - Authors recommend demonstration projects to show how to best implement HPV testing as primary screen, followed by cytology An analysis of 11 European and North American studies involving more than 60'000 women, published in the April issue of the International Journal of ...
Lugano/Johannesburg (ots) - HELSINN HEALTHCARE SA, and PFIZER LABORATORIES (PTY) LTD, announce the signing of an agreement granting PFIZER in South Africa, the exclusive license and distribution rights of Aloxi® (Palonosetron hydrochloride), a therapy for the prevention of nausea and vomiting induced by ...
Dreieich/Wolfsburg (ots) - The city of Wolfsburg is home to Volkswagen, the car makers. Its reputation to date has mainly been as a motor of progress in the development of modern production methods for the automotive industry. But Wolfsburg is now about to make a name for itself as a European pioneer in implementing better strategies for preventing cervical cancer. ...
Zurich (ots) - Baxter Healthcare S.A. announced today that Baxter"s ready-to-use liquid 10% Intravenous Immunoglobulin (IVIG), has received unanimous positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). Once licensed, ...